Work

Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists

Year: 2025

Type: article

Study designs: Systematic Review, Meta-Analysis

Source: Annals of Internal Medicine

DOI: 10.7326/annals-25-02237

Authors: Albert Ko, Yu-Cheng Chang, Furkan Bahar, Tsu Hsien Wang, Nutchapon Xanthavanij, Chun-Chiao Yu, Rebecca Jen-Ling Hsieh, Xin Ya See, Shao-Wei Lo, Junmin Song, Yuan Ping Hsia, Cho-Hung Chiang, Xiaocao Xu, Shuwen Lin, Cho-Han Chiang

Institutions: Harvard University, Danbury Hospital, Mount Auburn Hospital, University at Buffalo, State University of New York, Unity Health System, Unity Hospital, Kaohsiung Medical University, Albert Einstein College of Medicine, Jacobi Medical Center, Taipei Tzu Chi Hospital, Northwell Health, National Taiwan University Hospital, University of Vermont, University of Vermont Medical Center, Montefiore Medical Center, Montefiore Einstein Comprehensive Cancer Center

Language: English

Topic: Diabetes Treatment and Management

Subfield: Endocrinology, Diabetes and Metabolism

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4417183453

FWCI: 18.19

Cites: 79

Cited by: 31

Related to: